@article{1d08198e7db647ebb30ab52c0722777b,
title = "Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C",
abstract = "Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.",
keywords = "BOC, Boceprevir, CHC, Cost-effectiveness, DT, G1, ICER, NR, PAR, PI, PegIFN, RBV, RR, TVR, Telaprevir, boceprevir, chronic hepatitis C, dual therapy, genotype 1, incremental cost-effectiveness ratio, non-response, partial response, pegylated interferon, protease inhibitors, relapse, ribavirin, telaprevir, BOC, Boceprevir, CHC, Cost-effectiveness, DT, G1, ICER, NR, PAR, PI, PegIFN, RBV, RR, TVR, Telaprevir, boceprevir, chronic hepatitis C, dual therapy, genotype 1, incremental cost-effectiveness ratio, non-response, partial response, pegylated interferon, protease inhibitors, relapse, ribavirin, telaprevir",
author = "Antonio Gasbarrini and Matteo Ruggeri and Bruno, {Rosa Anna} and Calogero Camm{\`a} and Salvatore Petta and Giuseppe Cabibbo and Marco Enea and Raffaele Bruno and Vincenza Capursi and Alfredo Alberti and Antonio Crax{\`i}",
year = "2013",
doi = "10.1016/j.jhep.2013.05.019",
language = "English",
volume = "59",
pages = "658--666",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Blackwell Munksgaard:PO Box 2148, Periodicals Department, DK-1016 Copenhagen K Denmark:011 45 33 755913, EMAIL: agentservices@oxon.blackwellpublishing.com, INTERNET: http://www.blackwellmunksgaard.com, Fax: 011 45 77 333377",
}